SCHEMBL2916528

SCHEMBL2916528

CCCCN1C(=O)N(CCc2ccc(OC)cc2)C2(CCN(c3cccc(CC(=O)O)c3)CC2)C1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 1/20 0.43
HTR7 P34969 1/20 0.43
HTR6 P50406 1/20 0.43
ALDH1A1 P00352 2/20 0.39
TSHR P16473 2/20 0.39
USP2 O75604 1/20 0.39
CYP1A2 P05177 1/20 0.39
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HSD17B10 Q99714 1/20 0.39
ITGB3 P05106 2/20 0.38
ITGA2B P08514 2/20 0.38
FFAR4 Q5NUL3 1/20 0.38
MMP1 P03956 2/20 0.37
MMP9 P14780 2/20 0.37
MMP13 P45452 2/20 0.37
ADAM17 P78536 2/20 0.37
SIGMAR1 Q99720 2/20 0.37
FFAR1 O14842 1/20 0.36
CCR5 P51681 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2915783 0.90 HTR1A (0.41) HTR1AHTR7HTR6ALDH1A1TSHR
SCHEMBL2912440 0.89 HTR1A (0.41) HTR1AHTR7HTR6ALDH1A1TSHR
SCHEMBL2912597 0.88 FFAR4 (0.43) HTR1AHTR7HTR6ALDH1A1TSHR
SCHEMBL2917453 0.87 FFAR4 (0.42) HTR1AHTR7HTR6ALDH1A1TSHR
SCHEMBL2915308 0.83 HTR1A (0.43) HTR1AHTR7HTR6ALDH1A1TSHR
SCHEMBL13212951 0.83 HTR1A (0.38) HTR1AHTR7HTR6ALDH1A1TSHR
SCHEMBL2910436 0.82 PLA2G4A (0.41) HTR1AHTR7HTR6ALDH1A1TSHR
SCHEMBL2913320 0.82 HTR1A (0.39) HTR1AHTR7HTR6ALDH1A1TSHR
SCHEMBL2909474 0.81 CHRM4 (0.42) HTR1AHTR7HTR6ITGB3ITGA2B
SCHEMBL2909588 0.79 MCHR1 (0.37) HTR1AHTR7HTR6ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1979355-B1 SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2010-08-18 EP claimed
US-20090137610-A1 SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2009-05-28 US claimed
EP-1979355-B1 SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2010-08-18 EP disclosed
US-20090137610-A1 SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2009-05-28 US disclosed
US-20090137610-A1 SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2009-05-28 US disclosed
US-20090137610-A1 SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2009-05-28 US disclosed
EP-1979355-A1 SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2008-10-15 EP disclosed
WO-2007087448-A1 SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2007-08-02 WO disclosed
WO-2007087448-A1 SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137610-A1 SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS PPARD, PPARG, PPARA HTR1A 2163/4885HTR7 2222/4885HTR6 2012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.